Adjuvant Endocrine Treatment Strategies for Non-metastatic Breast Cancer: a Network Meta-analysis

Overview

Journal EClinicalMedicine

Specialty General Medicine

Date 2025 Mar 4

PMID 40034565

Authors

Andri Papakonstantinou

Guillermo Villacampa

Victor Navarro

Mafalda Oliveira

Antonios Valachis

Tomas Pascual

Alexios Matikas

Affiliations

Soon will be listed here.

Abstract

Background: Multiple trials have evaluated escalation strategies of endocrine therapy for early breast cancer, including ovarian function suppression (OFS) and aromatase inhibitors (AI) in premenopausal patients and extended endocrine therapy. However, several aspects remain controversial due to the heterogeneity of study designs and lack of statistical power in relevant subgroups. We aimed to investigate the optimal endocrine therapy strategy.

Methods: A systematic literature search was performed and last updated in August 2024 to identify randomized controlled trials (RCT) evaluating endocrine treatment strategies for hormone receptor positive breast cancer. A network meta-analysis with a frequentist framework using random-effects model was used to pool direct and indirect evidence. In addition, an extracted individual patient data meta-analysis was conducted to estimate the absolute differences between treatments. Study endpoints were disease-free survival (DFS), overall survival (OS), and safety. PROSPERO: CRD42023447979.

Findings: A total of 37 RCT that had enrolled 107,684 patients were included in the study. During the first five years, OFS + AI was the most effective strategy in premenopausal women, while AI or switch strategy showed the better efficacy results in postmenopausal ones. Following five years of tamoxifen, continuation with five additional years of AI was associated with improved 8-year DFS (85.8%) compared to no extended therapy (78.1%) or five additional years of tamoxifen (81.0%). Following five years of AI or switch strategy, extended treatment with AI improved DFS (Hazard Ratio = 0.81, 95% Confidence Interval 0.73-0.90).

Interpretation: This study provides information regarding the optimal endocrine treatment strategies for patients with resected hormone receptor positive early breast cancer.

Funding: None.

References

Michael Clark J, Sanders S, Carter M, Honeyman D, Cleo G, Auld Y . Improving the translation of search strategies using the Polyglot Search Translator: a randomized controlled trial. J Med Libr Assoc. 2020; 108(2):195-207. PMC: 7069833. DOI: 10.5195/jmla.2020.834. View

Blok E, Kroep J, Meershoek-Klein Kranenbarg E, Duijm-de Carpentier M, Putter H, van den Bosch J . Optimal Duration of Extended Adjuvant Endocrine Therapy for Early Breast Cancer; Results of the IDEAL Trial (BOOG 2006-05). J Natl Cancer Inst. 2017; 110(1). DOI: 10.1093/jnci/djx134. View

Glenny A, Altman D, Song F, Sakarovitch C, Deeks J, DAmico R . Indirect comparisons of competing interventions. Health Technol Assess. 2005; 9(26):1-134, iii-iv. DOI: 10.3310/hta9260. View

Stewart H, Prescott R, Forrest A . Scottish adjuvant tamoxifen trial: a randomized study updated to 15 years. J Natl Cancer Inst. 2001; 93(6):456-62. DOI: 10.1093/jnci/93.6.456. View

Goss P, Ingle J, Pritchard K, Robert N, Muss H, Gralow J . Extending Aromatase-Inhibitor Adjuvant Therapy to 10 Years. N Engl J Med. 2016; 375(3):209-19. PMC: 5024713. DOI: 10.1056/NEJMoa1604700. View

Sterne J, Savovic J, Page M, Elbers R, Blencowe N, Boutron I . RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019; 366:l4898. DOI: 10.1136/bmj.l4898. View

Tevaarwerk A, Wang M, Zhao F, Fetting J, Cella D, Wagner L . Phase III comparison of tamoxifen versus tamoxifen plus ovarian function suppression in premenopausal women with node-negative, hormone receptor-positive breast cancer (E-3193, INT-0142): a trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2014; 32(35):3948-58. PMC: 4251958. DOI: 10.1200/JCO.2014.55.6993. View

Ma S, Oladeru O, Singh A . Association of Endocrine Therapy With Overall Survival in Women With Small, Hormone Receptor-Positive, ERBB2-Negative Breast Cancer. JAMA Netw Open. 2020; 3(8):e2013973. PMC: 7445593. DOI: 10.1001/jamanetworkopen.2020.13973. View

Basch E . The missing voice of patients in drug-safety reporting. N Engl J Med. 2010; 362(10):865-9. PMC: 3031980. DOI: 10.1056/NEJMp0911494. View

10.

Gnant M, Dueck A, Frantal S, Martin M, Burstein H, Greil R . Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol. 2021; 40(3):282-293. PMC: 10476784. DOI: 10.1200/JCO.21.02554. View

11.

Kaufmann M, Jonat W, Hilfrich J, Eidtmann H, Gademann G, Zuna I . Improved overall survival in postmenopausal women with early breast cancer after anastrozole initiated after treatment with tamoxifen compared with continued tamoxifen: the ARNO 95 Study. J Clin Oncol. 2007; 25(19):2664-70. DOI: 10.1200/JCO.2006.08.8054. View

12.

Gnant M, Fitzal F, Rinnerthaler G, Steger G, Greil-Ressler S, Balic M . Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer. N Engl J Med. 2021; 385(5):395-405. DOI: 10.1056/NEJMoa2104162. View

13.

Bachelot T, Cottu P, Chabaud S, Dalenc F, Allouache D, Delaloge S . Everolimus Added to Adjuvant Endocrine Therapy in Patients With High-Risk Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer. J Clin Oncol. 2022; 40(32):3699-3708. DOI: 10.1200/JCO.21.02179. View

14.

Altman D, Andersen P . Calculating the number needed to treat for trials where the outcome is time to an event. BMJ. 1999; 319(7223):1492-5. PMC: 1117211. DOI: 10.1136/bmj.319.7223.1492. View

15.

Franzoi M, Agostinetto E, Perachino M, Del Mastro L, de Azambuja E, Vaz-Luis I . Evidence-based approaches for the management of side-effects of adjuvant endocrine therapy in patients with breast cancer. Lancet Oncol. 2021; 22(7):e303-e313. DOI: 10.1016/S1470-2045(20)30666-5. View

16.

Pagani O, Walley B, Fleming G, Colleoni M, Lang I, Gomez H . Adjuvant Exemestane With Ovarian Suppression in Premenopausal Breast Cancer: Long-Term Follow-Up of the Combined TEXT and SOFT Trials. J Clin Oncol. 2022; 41(7):1376-1382. PMC: 10419413. DOI: 10.1200/JCO.22.01064. View

17.

Dowsett M, Sestak I, Regan M, Dodson A, Viale G, Thurlimann B . Integration of Clinical Variables for the Prediction of Late Distant Recurrence in Patients With Estrogen Receptor-Positive Breast Cancer Treated With 5 Years of Endocrine Therapy: CTS5. J Clin Oncol. 2018; 36(19):1941-1948. PMC: 6049399. DOI: 10.1200/JCO.2017.76.4258. View

18.

Francis P, Fleming G, Lang I, Ciruelos E, Bonnefoi H, Bellet M . Adjuvant Endocrine Therapy in Premenopausal Breast Cancer: 12-Year Results From SOFT. J Clin Oncol. 2022; 41(7):1370-1375. PMC: 10419521. DOI: 10.1200/JCO.22.01065. View

19.

Andre F, Ismaila N, Allison K, Barlow W, Collyar D, Damodaran S . Biomarkers for Adjuvant Endocrine and Chemotherapy in Early-Stage Breast Cancer: ASCO Guideline Update. J Clin Oncol. 2022; 40(16):1816-1837. DOI: 10.1200/JCO.22.00069. View

20.

Del Mastro L, Mansutti M, Bisagni G, Ponzone R, Durando A, Amaducci L . Extended therapy with letrozole as adjuvant treatment of postmenopausal patients with early-stage breast cancer: a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021; 22(10):1458-1467. DOI: 10.1016/S1470-2045(21)00352-1. View